



**FOR IMMEDIATE RELEASE**

Tokyo, September 2, 2019

**JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan to Gilead Sciences K.K.**

Japan Tobacco Inc. (JT) (TSE:2914) announces today that the transfer date of the marketing approvals of six anti-HIV drugs<sup>1</sup> to Gilead Sciences K.K., the Japanese subsidiary of Gilead Sciences, Inc. (Gilead) is set for December 1, 2019. As announced in a press release<sup>2</sup> on December 14, 2018, JT and Gilead terminated the license agreements under which Gilead granted an exclusive license for JT to develop and commercialize six anti-HIV drugs in Japan, effective on January 1, 2019.

After the transfer of the marketing approvals has completed, Gilead K.K. will be responsible for the distribution of those six drugs which Torii Pharmaceutical Co., Ltd (Torii) (TSE:4551) is currently responsible for, under the terms and conditions for a provisional measure.

The transfer will have an immaterial effect on the business performance of both JT and Torii's in this fiscal year.

###

*Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With over 63,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under the Ploom brand and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.*

Contact for Japan Tobacco Inc.:  
Masahito Shirasu, General Manager  
Media and Investor Relations Division  
Japan Tobacco Inc. Tokyo: +81-3-5572-4292  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)

Contact for Torii Pharmaceutical Co., Ltd.:  
Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814

<sup>1</sup> "Viread® Tablets 300mg" "Emtriva® Capsules 200mg" "Truvada® Combination Tablets" "Stribild® Combination Tablets\*" "Genvoya® Combination Tablets\*" "Descovy® Combination Tablets LT/HT"

\*Stribild® combination tablets and Genvoya® combination tablets contain the active ingredient elvitegravir, discovered by JT. JT granted the exclusive rights for Gilead to develop and commercialize elvitegravir in all countries of the world.

<sup>2</sup> [https://www.jt.com/media/news/2018/pdf/20181214\\_E3.pdf](https://www.jt.com/media/news/2018/pdf/20181214_E3.pdf)